Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Advertisement

Advertisement




Jan
07
Today In Oncology
Intravesical Cretostimogene Grenadenorepvec Shows Strong High-Grade Recurrence-Free Survival in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer
IMvigor011 Subgroup Analysis: Role of ctDNA in Guiding Adjuvant Treatment for Muscle-Invasive Bladder Cancer
Study Finds Patients With Colon Cancer and Obesity Receiving GLP-1 RAs Had Significantly Reduced Risk of Mortality
A Novel Paradigm in Acute Kidney Injury Congestive Nephropathy in RCC With IVC Thrombus
Physical Activity and Fatigue QOL in Nonmetastatic CRC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo